AustralianSuper Pty Ltd Acquires 573 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AustralianSuper Pty Ltd grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,218 shares of the biopharmaceutical company’s stock after acquiring an additional 573 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Alnylam Pharmaceuticals were worth $993,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. New York State Teachers Retirement System lifted its position in shares of Alnylam Pharmaceuticals by 10.5% in the 4th quarter. New York State Teachers Retirement System now owns 5,836 shares of the biopharmaceutical company’s stock worth $1,373,000 after acquiring an additional 553 shares during the period. Van ECK Associates Corp lifted its position in shares of Alnylam Pharmaceuticals by 18.2% in the 4th quarter. Van ECK Associates Corp now owns 67,818 shares of the biopharmaceutical company’s stock worth $15,958,000 after acquiring an additional 10,419 shares during the period. Values First Advisors Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.3% in the 4th quarter. Values First Advisors Inc. now owns 8,992 shares of the biopharmaceutical company’s stock worth $2,116,000 after acquiring an additional 202 shares during the period. Summit Trail Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 13.3% in the 4th quarter. Summit Trail Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 151 shares during the period. Finally, Savant Capital LLC lifted its position in shares of Alnylam Pharmaceuticals by 57.6% in the 4th quarter. Savant Capital LLC now owns 11,738 shares of the biopharmaceutical company’s stock worth $2,762,000 after acquiring an additional 4,291 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.2 %

NASDAQ ALNY opened at $256.45 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock has a market capitalization of $33.08 billion, a P/E ratio of -97.88 and a beta of 0.35. The stock has a fifty day moving average of $254.03 and a 200-day moving average of $263.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALNY. Piper Sandler restated an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Raymond James raised their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Needham & Company LLC restated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Finally, TD Cowen raised their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $299.43.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold 73,964 shares of company stock worth $20,622,925 in the last three months. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.